Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Patient with HPV+ HNSCC dosed in Ph 1 ACESOT-1051 Trial

April 8, 2025

First Patient Dosed in ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

April 8, 2025

First Patient Dosed in Ph 1 Study of VVD-159642 for Treatment of Advanced Solid Tumors

April 8, 2025

First Patient Dosed in the Ph 3 Registrational Trial of ICP-248 + Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

April 2, 2025

Development of EO-3021 to be Discontinued

March 26, 2025

Vobramitamab duocarmazine (vobra duo) program to be discontinued

March 26, 2025

First Participant Dosed in Ph 3 Study of IBI354 for Platinum-resistant Ovarian Cancer

March 26, 2025

Ph 2 FIRCE-1 study of firicabtagene autoleucel (firi-cel) to be discontinued

March 26, 2025

Dosing Completed in the First Cohort of Ph 1 Study of NKT3964

March 18, 2025

Multikine Confirmatory Ph 3 Trial  in newly diagnosed locally advanced head and neck cancer patients to be Initiated

March 18, 2025

Metastatic breast cancer indication to be pursued for (Z)-endoxifen 

March 18, 2025

VERSATILE-003 Ph 3 Trial of Versamune HPV in HPV16-Positive Head and Neck Cancer Initiated

March 11, 2025

Patient Enrollment completed in Ph 3 Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent HCC

March 11, 2025

Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients in final stage of start-up preparations

March 11, 2025

First Patient Dosed in Ph 1 Study of ALTA3263 in Advanced Solid Tumors

March 11, 2025

First Patient Dosed in Dauntless-1 Ph 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer

March 11, 2025

Plans announced for Ph 2 trial of stenoparib + temozolomide for the treatment of recurrent SCLC

March 11, 2025

First-in-Human Treatment with HG-CT-1 for R/R AML

March 11, 2025

First Patient Dosed in Clinical Trial of IB-T101 for ccRCC

March 11, 2025

Accelerated Givastomig Ph 1b Study Progress Announced 

March 11, 2025

Independent Data Monitoring Committee (DMC) recommends a dose increase in the ongoing Ph 1/2a study TUMORAD-01 of 177Lu-SN201

March 11, 2025

Enrollment Completed in Ph 2 Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

March 11, 2025

CX-904 (EGFR-CD3 PROBODY TCE) program to be discontinued

March 11, 2025

Clinical Trial Application Submitted in Australia for CS5001 in Combination with 1L SOC for DLBCL

March 11, 2025

First Patient Dosed with EVM16 in patients with advanced or recurrent solid tumors

March 11, 2025
Page1 Page2 Page3 Page4 … Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.